Mahoney MR - Search Results

1

A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.

Pitot HC, Knost JA, Mahoney MR, Kugler J, Krook JE, Hatfield AK, Sargent DJ, Goldberg RM. Pitot HC, et al. Among authors: mahoney mr. Cancer. 2000 Oct 15;89(8):1699-705. Cancer. 2000. PMID: 11042563 Clinical Trial.

2

CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.

Alberts SR, Fishkin PA, Burgart LJ, Cera PJ, Mahoney MR, Morton RF, Johnson PA, Nair S, Goldberg RM; North Central Cancer Treatment Group. Alberts SR, et al. Among authors: mahoney mr. Int J Gastrointest Cancer. 2002;32(2-3):107-14. doi: 10.1385/ijgc:32:2-3:107. Int J Gastrointest Cancer. 2002. PMID: 12794246 Clinical Trial.

3

Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.

Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Alberts SR, et al. Among authors: mahoney mr. Cancer. 2005 Jan 1;103(1):111-8. doi: 10.1002/cncr.20753. Cancer. 2005. PMID: 15558814 Free article. Clinical Trial.

4

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.

Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Alberts SR, et al. Among authors: mahoney mr. J Clin Oncol. 2005 Dec 20;23(36):9243-9. doi: 10.1200/JCO.2005.07.740. Epub 2005 Oct 17. J Clin Oncol. 2005. PMID: 16230673 Clinical Trial.

5

Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248.

Alberts SR, Kim GP, Mahoney MR, Gornet MK, Rubin J, Ames M, Goetz MP, Weinshilboum RM, Nicol SJ, Goldberg RM. Alberts SR, et al. Among authors: mahoney mr. Clin Colorectal Cancer. 2007 Jul;6(8):572-7. doi: 10.3816/CCC.2007.n.024. Clin Colorectal Cancer. 2007. PMID: 17681103 Clinical Trial.

6

Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma.

Hobday TJ, Kugler JW, Mahoney MR, Sargent DJ, Sloan JA, Fitch TR, Krook JE, O'Connell MJ, Mailliard JA, Tirona MT, Tschetter LK, Cobau CD, Goldberg RM. Hobday TJ, et al. Among authors: mahoney mr. J Clin Oncol. 2002 Dec 1;20(23):4574-80. doi: 10.1200/JCO.2002.08.535. J Clin Oncol. 2002. PMID: 12454115 Clinical Trial.

7

Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program.

Goldberg RM, Sargent DJ, Morton RF, Mahoney MR, Krook JE, O'Connell MJ. Goldberg RM, et al. Among authors: mahoney mr. J Clin Oncol. 2002 Dec 1;20(23):4591-6. doi: 10.1200/JCO.2002.03.039. J Clin Oncol. 2002. PMID: 12454117 Review.

8

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J. Ansell SM, et al. Among authors: mahoney mr. Cancer. 2001 Apr 15;91(8):1543-8. doi: 10.1002/1097-0142(20010415)91:8<1543::aid-cncr1163>3.0.co;2-n. Cancer. 2001. PMID: 11301403 Clinical Trial.

9

Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.

Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O'Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE; North Central Cancer Treatment Group. Garrity MM, et al. Among authors: mahoney mr. J Clin Oncol. 2004 May 1;22(9):1572-82. doi: 10.1200/JCO.2004.10.042. J Clin Oncol. 2004. PMID: 15117979

10

Dealing with a deluge of data: an assessment of adverse event data on North Central Cancer Treatment Group trials.

Mahoney MR, Sargent DJ, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC. Mahoney MR, et al. J Clin Oncol. 2005 Dec 20;23(36):9275-81. doi: 10.1200/JCO.2004.00.0588. J Clin Oncol. 2005. PMID: 16361625

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page